S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
How major US stock indexes fared Thursday, 4/11/2024
Blackstone’s $10 Billion Bet on Property Prices Going Up
Closing prices for crude oil, gold and other commodities
PriceSmart Could Be the Smartest Buy of the Year
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
How major US stock indexes fared Thursday, 4/11/2024
Blackstone’s $10 Billion Bet on Property Prices Going Up
Closing prices for crude oil, gold and other commodities
PriceSmart Could Be the Smartest Buy of the Year
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
How major US stock indexes fared Thursday, 4/11/2024
Blackstone’s $10 Billion Bet on Property Prices Going Up
Closing prices for crude oil, gold and other commodities
PriceSmart Could Be the Smartest Buy of the Year
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
How major US stock indexes fared Thursday, 4/11/2024
Blackstone’s $10 Billion Bet on Property Prices Going Up
Closing prices for crude oil, gold and other commodities
PriceSmart Could Be the Smartest Buy of the Year

Arcellx (ACLX) Stock Price, News & Analysis

$60.17
+1.09 (+1.84%)
(As of 04/11/2024 ET)
Today's Range
$59.22
$60.48
50-Day Range
$59.08
$73.49
52-Week Range
$28.03
$75.10
Volume
326,594 shs
Average Volume
442,390 shs
Market Capitalization
$3.18 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$74.17

Arcellx MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
23.3% Upside
$74.17 Price Target
Short Interest
Bearish
9.85% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.65mentions of Arcellx in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$41.92 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.69) to ($1.65) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.75 out of 5 stars

Medical Sector

1987th out of 2,796 stocks

Biotechnology Industry

109th out of 165 stocks

ACLX stock logo

About Arcellx Stock (NASDAQ:ACLX)

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

ACLX Stock Price History

ACLX Stock News Headlines

Weiss issues 'Buy' on AI sleeper stock
Based on our Weiss Ratings, we’ve issued a “Buy” on an under-the-radar AI stock. And we share the details at our Artificial Intelligence Town Hall ….
Weiss issues 'Buy' on AI sleeper stock
Based on our Weiss Ratings, we’ve issued a “Buy” on an under-the-radar AI stock. And we share the details at our Artificial Intelligence Town Hall ….
ACLX Apr 2024 70.000 call
William Blair Reaffirms Their Buy Rating on Arcellx Inc (ACLX)
See More Headlines
Receive ACLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcellx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/12/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ACLX
Fax
N/A
Employees
130
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$74.17
High Stock Price Target
$87.00
Low Stock Price Target
$50.00
Potential Upside/Downside
+23.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
12 Analysts

Profitability

Net Income
$-70,690,000.00
Pretax Margin
-63.48%

Debt

Sales & Book Value

Annual Sales
$110.32 million
Book Value
$9.97 per share

Miscellaneous

Free Float
49,703,000
Market Cap
$3.18 billion
Optionable
Optionable
Beta
0.02
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives


ACLX Stock Analysis - Frequently Asked Questions

Should I buy or sell Arcellx stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcellx in the last year. There are currently 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACLX shares.
View ACLX analyst ratings
or view top-rated stocks.

What is Arcellx's stock price target for 2024?

12 Wall Street analysts have issued 12 month price targets for Arcellx's stock. Their ACLX share price targets range from $50.00 to $87.00. On average, they predict the company's stock price to reach $74.17 in the next twelve months. This suggests a possible upside of 23.3% from the stock's current price.
View analysts price targets for ACLX
or view top-rated stocks among Wall Street analysts.

How have ACLX shares performed in 2024?

Arcellx's stock was trading at $55.50 on January 1st, 2024. Since then, ACLX shares have increased by 8.4% and is now trading at $60.17.
View the best growth stocks for 2024 here
.

When is Arcellx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our ACLX earnings forecast
.

How were Arcellx's earnings last quarter?

Arcellx, Inc. (NASDAQ:ACLX) issued its quarterly earnings data on Wednesday, February, 28th. The company reported $0.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.53) by $0.95. The firm had revenue of $63.15 million for the quarter, compared to the consensus estimate of $20.07 million. Arcellx had a negative net margin of 64.08% and a negative trailing twelve-month return on equity of 20.96%. During the same quarter in the previous year, the business earned ($0.76) earnings per share.

What ETF holds Arcellx's stock?

ALPS Medical Breakthroughs ETF holds 36,367 shares of ACLX stock, representing 1.10% of its portfolio.

When did Arcellx IPO?

Arcellx (ACLX) raised $132 million in an initial public offering on Friday, February 4th 2022. The company issued 8,250,000 shares at $15.00-$17.00 per share.

Who are Arcellx's major shareholders?

Arcellx's stock is owned by a variety of institutional and retail investors. Top institutional investors include Congress Asset Management Co. MA (0.04%). Insiders that own company stock include Christopher Heery, Enterprise Associates 15 New, Jill Carroll, Michelle Gilson, Olivia C Ware, Rami Elghandour, Scott D Sandell and Sr One Capital Management, Llc.
View institutional ownership trends
.

How do I buy shares of Arcellx?

Shares of ACLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACLX) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners